- Details
- In this UroToday Journal Club, Zachary Klaassen highlights the JAMA oncology publication Disparities in the Inclusion of Racial and Ethnic Minority Groups and Older Adults in Prostate Cancer Clinical Trials: A Meta-analysis. Mandates have been put in place to emphasize both the importance of including racial and ethnic minorities in clinical trials and the reporting of the demographics of these tr...
|
- Details
- In this UroToday Journal Club, Zachary Klaassen discusses the publication titled Shorter Radiation Regimens and Treatment Non-Completion Among Patients with Breast and Prostate Cancer in the United States: An Analysis of Racial Disparities in Access and Quality. The goal of this analysis is to assess trends in the uptake of shorter radiation regimes with a focus on the data for prostate cancer and...
|
- Details
- Zachary Klaassen and Christopher Wallis dissect key updates to the NCCN Prostate Cancer Guidelines. Their focus lies on systemic therapy for mCRPC, specifically the latest modifications concerning PARP inhibitors. They reveal that men treated with androgen derivation therapy (ADT) for advanced prostate cancer will often progress to castration resistance. For those who reach this stage, continued A...
|
- Details
- In this UroToday Journal Club, Zachary Klaassen highlights the European urology publication titled "Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 2: Interpretation." It is generally felt that MRI is superior to other imaging techniques, including CT scans, for soft tissue assessment. This data focuses on h...
|
- Details
- In this UroToday Journal Club, Zachary Klaassen highlights the Journal of clinical oncology publication of the phase II SALV-ENZA Trial which sought to investigate whether enzalutamide, without concurrent androgen deprivation therapy, increases freedom from prostate-specific antigen progression when combined with salvage radiation therapy in men with recurrent prostate cancer after radical prostat...
|
- Details
- In this UroToday Journal Club, Zachary Klaassen highlights the Urologic Oncology publication entitled Out-of-pocket costs for commercially insured patients with localized prostate cancer. Financial burdens may contribute to long-term effects on patient's health-related quality of life. However, costs are rarely included in shared decision-making conversations, and most studies available have focus...
|
- Details
- Zachary Klaassen discusses The Journal of Urology publication entitled "Association Between Treatment for Localized Prostate Cancer and Mental Health." This study compares patient-reported mental health outcomes for men undergoing treatment for localized prostate cancer over 5 years using the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study. Biographies: Zachary Klaassen,...
|
- Details
- In this UroToday Journal Club, Zach Klaassen highlights a European Urology Oncology publication entitled Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-Based Biopsy in Men on Active Surveillance for Prostate Cancer -- Data from the Multi-International Multicenter Prospective PRIAS Study . In general, the use of MRI prior to initial biopsy is now relatively widely manda...
|
- Details
- In this UroToday Journal Club, Zach Klaassen highlights a European Urology publication entitled High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium . Radiotherapy is a standard-of-care treatment approach for patients with localized prostate cancer, and t...
|
- Details
- In this UroToday Journal Club, Zachary Klaassen reviews the PROpel study and the New England Journal of Medicine Evidence publication entitled Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer . PROpel is a randomized phase III trial of abiraterone plus olaparib versus abiraterone plus placebo as first-line therapy for patients with metastatic castration-resistant prosta...
|
